Purpose Gestational diabetes mellitus (GDM) is the most frequent complication of pregnancy; around 10% of GDM cases may be determined by autoimmunity, and our aims were to establish the role of autoimmunity in a population of Sardinian women affected by GDM, to find predictive factors for autoimmune GDM, and to determine type 1 diabetes (T1D) autoantibodies (Aabs) together with glucose tolerance after a mean 21.2 months of follow-up. Methods We consecutively recruited 143 women affected by GDM and 60 without GDM; clinical data and pregnancy outcomes were obtained by outpatient visit or phone recall. T1D auto-antibodies GADA, IA2-A, IAA, ZnT8-A were measured in the whole population at baseline, and in the Aab-positive women at follow-up. Results The overall prevalence of autoimmunity was 6.4% (13/203). No significant difference was found in the prevalence of auto-antibodies between GDM (5.6%) and control (8.3%) women, neither in antibody titres. Highest titres for GADA and ZnT8-A were observed in the control group; no phenotypic factors were predictive for autoimmune GDM. Diabetesrelated autoantibodies were still present in all the GDM women at follow-up, and their presence was associated with a 2.65 (p < 0.0016) relative risk (RR) of glucose impairment. Conclusion We observed a low prevalence (5.6%) of diabetes-related autoimmunity in our GDM cohort, consistent with the prevalence reported in previous studies. It was not possible to uncover features predictive of autoimmune GDM. However, given the significant risk of a persistent impaired glycemic regulation at follow-up, it is advisable to control for glucose tolerance in GDM women with diabetes-related autoimmunity.
Introduction
Gestational diabetes mellitus (GDM) is defined as diabetes diagnosed in the second or third trimester of pregnancy that is not clearly overt diabetes [1] . GDM is the most frequent complication of pregnancy, with prevalence between 2 and 17%, depending on genetic background, diagnostic criteria and screening measures [2] [3] [4] [5] [6] .
The prevalence of GDM usually follows that of type 2 diabetes (T2DM) in the reference population; in Italy, its prevalence varies between 2 and 12% (with an average of 7%) [7] . However, in Sardinia, a higher frequency around 22 .3% has been reported, almost 3 times the national average, although these data come from a single study [8] .
GDM reflects the pathogenesis of T2DM, with insulin resistance playing a pivotal role. Pregnancy is "per se" a diabetogenic condition, and its only because of beta-cells adaptability that glucose homeostasis is maintained, despite the progressive physiologic insulin resistance [9] . In the last decade, several studies found that in some cases of GDM, a deficit in insulin secretion may be determined by an autoimmune damage of beta cells, following the presence of autoantibodies; this accounts for around 10% of all the cases of GDM, and it is significant since it identifies a subgroup of women with at higher risk for future T1D [10] .
GDM is a risk condition for both the mother and the fetus, possibly determining short-term complications (such as pre-eclampsia or fetal macrosomy), but also long-term risks, such as the risk to develop diabetes later in life in both the mother and child. While the risk for GDM women to develop T2DM is well known, it is not the same for the risk of developing T1D; some studies, as those of Nilsson [11] and Yu [12] , show high rate of glucose impairment when autoantibody positivity is present in gestation (up to 50% of autoantibody-positive pregnancies will develop T1D, half of them within 1 year [11] ).
Given that there are very few studies on autoimmune GDM in populations at high-risk for T1D such as the Finnish [13] or Sardinian, and considering the apparently higher prevalence in Sardinia of GDM, as reported by Murgia et al. [8] , the aim of this work was to evaluate the prevalence of diabetes-related autoimmunity in a non-selected population of Sardinian women with GDM, and in a control group matched for gestational age and number of deliveries. Also, we assessed autoimmune-related phenotypic features in women with GDM, such as age, low pre-gestational BMI, higher blood glucose levels at OGTT, to look for possible predictive factors of autoimmune GDM, and thus to try to identify which women to test for antibodies. Finally, we aimed to determine the risk of T1D in women with diabetes-related autoimmunity by re-assessing T1D autoimmunity and glucose tolerance in autoantibody-positive women after a median 21.2 months (range 8.0-31.0) of follow-up from pregnancy.
Materials and methods

Subjects
A total of 143 women affected by GDM were consecutively recruited in the Diabetes Unit of the University Hospital of Cagliari, between April 2010 and February 2016. The diagnosis of GDM was based on the oral glucose tolerance test (OGTT), according to ADA 2017 guidelines [1] .
As control group, we recruited consecutively sixty pregnant women without GDM according to the OGTT, matched for gestational age and number of deliveries. The OGTT was carried out in the same hospital and in the same period of the GDM women. Information on clinical data of GDM women (age, gestational age, BMI, therapies, number of deliveries, family history of diabetes, concomitant diseases, even autoimmune diseases, miscarriage or GDM or macrosomia history in previous pregnancies, impaired glucose tolerance before pregnancy) was obtained from electronic medical records. Information on pregnancy outcomes (delivery mode, gestational age at delivery, the presence of macrosomy or other fetal-neonatal complications) was obtained by outpatient visit or telephone recall and was available for 68/143 of the total sample.
The time of follow-up for the autoantibody-positive and autoantibody-negative women varied between 10.4 months and 31 months (mean 21.2 ± 16.2 months) after the pregnancy with GDM. At follow-up, women with previous autoantibodies were reanalyzed for all 4 autoantibodies (GADA, IA-2A, IAA and ZnT8-A), and underwent a new OGTT. We also re-assessed for glucose tolerance 35 of the ab-negative GDM women that returned for control (mean time to follow-up 19.0 ± 13.7 months).
Glutamic Acid Decarboxylase Antibody (GADA), Tyrosine Phosphatase-related Islet Antigen 2 Antibody (IA2-A) and Insulin Antibodies (IAA) measurements were performed on serum samples by sensitive radioimmunoassay (RSR Limited, Cardiff, UK). The upper normal limit is ≤ 1 U/mL for GADA and IA2-A and ≤ 0.4 U/mL for IAA. From manufacturer's specifications, GADA assay has an intra-assay coefficient of variation (CV) of 3.6% and an interassay CV between 4.9 and 7.0%. IA2-A assay has intra-and interassay CVs of 2.5-2.8% and of 3.3-5.3%, respectively. IAA assay has intra-and interassay CVs of 3.0% to 5.8% and of 4.2 and 6.7%, respectively. ZnT8A were detected by ELISA (RSR Limited, Cardiff, UK). The upper limit for ZnT8-A is < 15 U/mL; values between 10 and 14 are considered borderline. ZnT8-A interassay CV is 7.5-9.3% and intra-assay CV is 3.5-6.2%. The Laboratory of Diabetes of the University of Cagliari, Italy, participated to the 2009 Diabetes Autoantibody Standardization Program (DASP), and achieved 95.7% specificity and 76% sensitivity for GADA and 98.9% specificity and 64% sensitivity for IA-2A [14] .
Serum glucose concentrations were measured by glucoseoxidase method (Autoanalyzer, Beckman Coulter, USA). Serum insulin concentrations were measured on frozen samples by radio-immuno assay (DLS-1600 kit test, Inc, Webster, Texas, USA) that has intra-assay CV between 4.7 and 12.2% and interassay CV between 4.5 and 8.3%. Insulin resistance was assessed by the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR).
Statistical analysis
Continuous variables are shown as average ± standard deviation (DS) or as median and Interquartile range 1 3
(IQR), depending on their distribution (respectively, normal or non normal). To evaluate the distribution, the Kolmogorov-Smirnov test was used. Categorical variables are expressed as numbers and/or percentage. Differences between variables were evaluated by 2-tailed Student t test or Mann-Whitney test, as appropriate. Categorical variables were compared by chi-square or Fisher exact test. P < 0.05 was taken as statistically significant. The Statistical Package for the Social Sciences (SPSS) version 20 (IBM Corp., Armonk, NY) was used to perform the analyses.
Ethics statement
The study was reviewed and approved by the Ethical Committee of Azienda Ospedaliero-Universitaria of Cagliari, Italy, and conducted in conformance with the Helsinki Declaration. Written consent was obtained from all subjects before the study.
Results
Population characteristics are shown in Table 1 . GDM patients differed from control women in age, fasting glycemia, HOMA-IR and BMI at diagnosis, all significantly higher in GDM. There was also an increased prevalence of family history for diabetes mellitus (57.3%) and a higher prevalence of other autoimmune diseases (24.5%) in GDM patients, although not significant.
Of the 143 women in the GDM group, 60.2% were at their first pregnancy, 30.1% had at least one miscarriage, 20.2% had GDM in a previous pregnancy and 12.3% had impaired glucose tolerance before pregnancy. Pre-pregnancy BMI, available for around 50% of the population, had a median value of 23.90 kg/m 2 (IQR 7.2).
Prevalence of diabetes-related autoimmunity
The overall prevalence of diabetes-related autoimmunity ( Fig. 1) in all the 203 women tested (143 with GDM + 60 without GDM) was 6.4% (13/203) . No significant difference in diabetes-related autoimmunity was found between the two groups (Fig. 2) ; 5.6% (8/143) of GDM women were positive for at least one autoantibody (vs 8.3% of NTG group, p = 0.47) and, more specifically, GADA were present in 4.2% (6/143) of GDM women vs 6.7% of the control group (4/60; p = 0.46), IA2-A were present in 1.4% (2/143; p = 0.36) of the GDM group and absent in the control group; ZnT8-A were observed in 1.4% (2/143) of the GDM women but they were found also in 1.7% of control women (1/60; p = 0.89). Two women in the GDM group (1.4%) had double antibody positivity (GADA + IA2-A). The positivity for IAA was absent in both groups. Also, a previous history of impaired glucose tolerance or GDM 
Autoantibody and clinical and metabolic parameters
We then compared clinical e metabolic parameters in autoantibody-positive and autoantibody-negative women (Table 2 ); no significant difference was observed between the two groups in age, gestational week of diagnosis, fasting blood insulin levels and insulin-resistance index. Also between the GDM groups, the presence of autoantibodies did not associate with any difference in the parameters tested, including similar glycemic levels at OGTT (data not shown).
According to medical records, two out of 8 (25%) GDM women with autoimmune positivity were treated with insulin during pregnancy. They both had higher GADA levels compared to the others. Insulin therapy was also started in 48% of the autoantibody-negative GDM women. No differences were observed in the pregnancy outcomes relative to insulin treatment.
Follow-up
In total, 41 of the GDM women were re-assessed, together with 3 autoantibody-positive non-GDM women (total 44). Of the 13 autoantibody-positive women, nine were re-evaluated after a mean 34.2 ± 16.3 months; 6 women with previous GDM and the three control Aab-positive women. All women with previous GDM and Aab-positivity were autoantibody positive at follow-up (supplementary Table 1 ). In particular, all 6 were GADA positive, 2/6 IA2 positive, one was positive for low titres of IAA and none carried ZnT8-A. All women showed the same positivity as at baseline. Furthermore, although other autoimmune disorders were more frequent in Aab-positive GDM women (3/6, 1 with coeliac disease and 2 with thyroiditis), there was no significant difference in the prevalence of autoimmune disorders between Aab-positive and Aab-negative women (7/35, all with thyroiditis). The 6 autoantibody-positive GDM patients underwent an OGTT at follow-up, which showed impaired glucose regulation in 5 of them. Specifically, 5 out of 6 had fasting glucose levels above normal range (IFG). Within the 3 autoantibody-positive women with normal pregnancies, one was GADA-positive, although at low titre, and another was ZnT8A-positive (titre = 50 U/mL), as before.
Of the 35 women with GDM without T1D autoantibodies, 24 had a normal OGTT and 11 (31.4%) had IFG.
The relative risk (RR) of having glucose abnormalities if autoantibody-positive at the time of baseline pregnancy was 2.65 (95% CI = 1.45-4.86, p < 0.0016).
Discussion
In this study we observed a low prevalence of beta-cell autoantibodies in women with GDM from Sardinia. Although in Sardinia a higher prevalence of autoimmunity was expected on the basis of the genetic background and on the well-known high prevalence of T1D [13] [14] [15] [16] [17] [18] , we indeed observed a lower than expected prevalence (6.4%) of diabetes-related autoimmunity in our cohort of pregnant women. This prevalence is similar and consistent with many studies in GDM women, where prevalence between 0 and 10% has been reported, as reviewed by Lapolla et al. [10] .
Nevertheless, our results are at variance with what has been reported in the only previous study in Sardinian women [19] , where 38.8% of Sardinian women with GDM showed positivity for at least one antibody (vs 7.1% in their control group). Furthermore, in the study by Murgia et al. [19] , there were also important differences related to single antibodies positivity: the more frequent antibody was IA2-A (29%), whereas GADA was the less frequent (3.2%). These results, as discussed before, are also in contrast with other three previous studies in the Italian population [20] [21] [22] .
Our study is the second, after Murgia et al. [19] , to look at GADA, IA2-A and IAA in a cohort of Sardinian women with GDM. These two works examined a population similar for ethnicity, gestational age, parity grade and pre-gravidic BMI. However, the results are clearly different, with a much lower prevalence of autoantibody positivity in our cohort. These discrepancies may have different explanations. For example, sample selection and screening criteria; we did not exclude patients with previous GDM (about 20 .2% of our GDM women) as they did, and they used the two step OGTT [8] with a lower glucose threshold at 3 h (130 mg/ dl), whilst we adopted current recommendations and used the OGTT with 75 g glucose in our study. It is possible, therefore, that they observed an excess of diagnoses based on the type of test. Another important point is the different autoimmune measurement tools: they used a method with a lower cut-off value for autoantibody positivity, possibly leading to a reduced specificity.
Our results show that only 5.6% of GDM women resulted positive to at least one autoantibody (vs 8.3% of NGT women, p = 0.47), and the most frequent antibody was GADA (4.2%, 6/143); also, differently from what reported by Murgia et al. [19] , the prevalence of IA2-A in our study was very low. Furthermore, no IAA positivity was found in our GDM women nor in controls, against a prevalence of 14.5, 5.9 and 3% reported by Murgia, Jarvela and Dozio, respectively [13, 19, 20] . Our result is consistent with the very unusual presence of IAA in adult age [23] , as was absent in our cohort, compared to the expected higher frequency of IAA in DMT1 children (age < 15 years).
For the first time, we also examined the prevalence of ZnT8-A in the Italian GDM population, which resulted lower (only in 2 of our GDM women) than that reported in the only two studies testing ZnT8-A [24, 25] , but, as in these studies, also in our population this autoantibody was positive in women without GADA and IA2-A positivity. The clinical meaning of this single low-titre ZnT8-A positivity is not clear. ZnT8 auto-antibodies may be an independent marker of islet autoimmunity in a proportion of women with gestational diabetes [24] ; however, it is probably necessary to identify specific thresholds in gestational diabetes before any clinical significance can be discussed.
Regarding the autoantibody titres, it has been evaluated in different studies in autoimmune GDM women: they all confirm low titres, especially if compared with the titres observed in newly diagnosed T1D or in first-degree relatives of patients with T1D [26, 27] . Conflicting results are reported on the differences in autoantibody titres between GDM women and control group women, especially for GADA and IA2-A; however, the majority show no differences between GDM women and controls [10, 26] . Similarly, in our GDM population, GADA and IA2-A titres were low, and this finding suggests that, in our population, the major underling mechanism for GDM may not be betacell autoimmunity. This point is in agreement also with the fact that antibody positivity in our women did not relate to more severe insulin secretion impairment: we did not observe a higher prevalence of insulin therapy, nor higher glycemic levels at OGTT, and not even phenotypic features related to a lower insulin resistance (no differences found in BMI, fasting insulinemia and HOMA-IR). On the other hand, previous studies are discordant, with some authors finding no differences in clinical features between women with autoimmune GDM and women without autoimmunity [20, 28, 29] , and other authors reporting that autoimmune GDM is associated with a lower BMI, a more frequent need for insulin therapy and a more severe clinical manifestation, with higher blood glucose levels [30, 31] . As observed in previous studies [22, 25] we found no difference in maternal-fetal outcomes between women with or without autoimmunity, suggesting that the main determinant of these pregnancy outcomes is hyperglycaemia, whatever the cause [32] .
After a mean 21.2 months, we performed a follow-up visit, which included a control OGTT, in 41 of the GDM women, five out of 6 of the autoantibody-positive women with previous GDM resulted IFG. All presented the same autoantibody positivity that they had at baseline. At variance with the studies of Nilsson [11] and Yu [12] , we did not have any case of diabetes in our autoantibody-positive women, although their median follow-up was longer (7 years). However, in their study 50% developed T1DM within 1 year. One possible explanation is that, in our study, autoantibody titres were low, possibly suggesting a less aggressive autoimmunity. As in other studies [24, 31, 33] GADA was the most frequent autoantibody (100% in women with GDM).
Finally, comparing autoantibody-positive women with the autoantibody-negative women with GDM we observed a highly significant relative risk (RR = 2.65) of remaining with an impaired glucose regulation at follow-up.
With regards to the immunological state in pregnancy, it is well known that the maternal immune system plays a critical role in the establishment, maintenance, and completion of a healthy pregnancy [10] . During pregnancy, hormonal changes influence the cytokine profiles, and a T helper 1 (Th1)/T helper 2 (Th2) immune shift during pregnancy is well established [34] . Thus, during pregnancy the shift towards a Th2-mediated immunomodulation suppresses autoimmunity and protects towards infections. However, in the post-partum period when Th2-type cytokines decreases, Th1 autoimmune disorders could worsen. Therefore, through these processes, the immune system would be able to influence autoimmunity both during the gestational period (positively) and in the postpartum, but also decades later [34] . So women with autoimmune GDM run a higher risk of developing type 1 diabetes or, more probably, LADA [35] . Additionally, given this higher risk, it could be useful, if glucose impairment persists and in the absence of evident insulin-resistance features, to determine diabetes-related autoimmunity in the follow-up of GDM women.
Strengths of our work are the relatively large sample size (a total of 203 pregnant women) in comparison to other studies (as reviewed by Mauricio et al. [35] ), the more detailed evaluation of phenotypic features of the studied subjects, including insulin resistance and blood glucose levels impairment, and the evaluation of the possible impact of antibody positivity on pregnancy-and maternal -fetal outcomes. Although we had fewer control women, they were selected as close as possible to the GDM women, also excluding those that were tested only with the 50 g glucose test. Additionally, we were able to evaluate the predictive role of autoantibody positivity on glucose regulation after follow-up. Finally, ours is one of the very few studies performed in populations at high risk for autoimmune diabetes [13] .
The main limitation of our work is that some of the data, for example pre-pregnancy BMI or information on pregnancy outcomes, was available only for a subgroup of patients (around 50%). This is because of an incomplete filling of medical records, no answer to phone recall, and also to the low adherence to post-delivery follow-up. Almost 40% of GDM women did not repeat the OGTT after 6-12 weeks from delivery, as recommended by current guidelines [1] . This low rate is in line with what pointed out in the literature [36] , and put emphasis on the need for more patients' education on the long-term GDM complications, to increase the opportunity for prevention of diabetes, metabolic syndrome and cardiovascular complications.
Conclusions
From this study in Sardinian women we observed that, contrary to what expected, diabetes-related autoimmunity is not a main factor in the etiology of GDM in Sardinia, accounting for less then 5.6% of cases. GADA resulted the most frequent autoantibody, with similar frequencies in GDM and NGT women, suggesting that antibody positivity does not correlate with greater beta-cell impairment. As in other studies [20, 28, 29] , it was not possible to find predictive GDM features to define which patients to screen for autoantibodies, since autoimmune positivity in our population did not relate to phenotypic features significantly different from the ones observed in autoimmune-negative women. Although we did not have complete data on the outcomes, in the 50% of women where data were available no difference was observed in maternal-fetal outcomes among women with or without markers of autoimmunity, suggesting that the main determinant of pregnancy outcomes is hyperglycaemia, whatever the cause. Finally, the presence of T1D-related auto-antibodies during pregnancy was associated with a greater risk (RR 2.65) of having impaired glucose regulation after a mean 21.2 months of follow-up, suggesting that the autoimmune process may be continuing to impair beta-cell function.
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